NRIX - IPO Update: Kymera Therapeutics Readies $125 Million IPO
Quick Take
Kymera Therapeutics (KYMR) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is advancing treatment candidates for skin and immune system conditions.
KYMR is still some time away from beginning Phase 1 safety trials for its lead candidate, so the IPO may be more suited to long-term hold institutional investors.
Company & Technology
Watertown, Massachusetts-based Kymera was founded to create treatment options for hidradenitis suppurativa [HS] and atopic dermatitis [AD] as well as other immune system mediated conditions.